Last reviewed · How we verify
ACT500 tablets
At a glance
| Generic name | ACT500 tablets |
|---|---|
| Sponsor | Xiamen Amoytop Biotech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD) (PHASE1)
- Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACT500 tablets CI brief — competitive landscape report
- ACT500 tablets updates RSS · CI watch RSS
- Xiamen Amoytop Biotech Co., Ltd. portfolio CI